CN106687481B - 半乳糖改造的免疫球蛋白1抗体 - Google Patents

半乳糖改造的免疫球蛋白1抗体 Download PDF

Info

Publication number
CN106687481B
CN106687481B CN201580048480.1A CN201580048480A CN106687481B CN 106687481 B CN106687481 B CN 106687481B CN 201580048480 A CN201580048480 A CN 201580048480A CN 106687481 B CN106687481 B CN 106687481B
Authority
CN
China
Prior art keywords
antibodies
population
antibody
relative frequency
galactose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580048480.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN106687481A (zh
Inventor
S·马利克
D·罗伊施
A·施努尔里格
M·L·特哈达
M·托曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to CN202111538475.2A priority Critical patent/CN114181312A/zh
Publication of CN106687481A publication Critical patent/CN106687481A/zh
Application granted granted Critical
Publication of CN106687481B publication Critical patent/CN106687481B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580048480.1A 2014-09-10 2015-09-04 半乳糖改造的免疫球蛋白1抗体 Expired - Fee Related CN106687481B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111538475.2A CN114181312A (zh) 2014-09-10 2015-09-04 半乳糖改造的免疫球蛋白1抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14184201 2014-09-10
EP14184201.3 2014-09-10
US201462095912P 2014-12-23 2014-12-23
US62/095,912 2014-12-23
PCT/EP2015/070285 WO2016037947A1 (en) 2014-09-10 2015-09-04 Galactoengineered immunoglobulin 1 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111538475.2A Division CN114181312A (zh) 2014-09-10 2015-09-04 半乳糖改造的免疫球蛋白1抗体

Publications (2)

Publication Number Publication Date
CN106687481A CN106687481A (zh) 2017-05-17
CN106687481B true CN106687481B (zh) 2022-03-22

Family

ID=51518624

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580048480.1A Expired - Fee Related CN106687481B (zh) 2014-09-10 2015-09-04 半乳糖改造的免疫球蛋白1抗体
CN202111538475.2A Pending CN114181312A (zh) 2014-09-10 2015-09-04 半乳糖改造的免疫球蛋白1抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111538475.2A Pending CN114181312A (zh) 2014-09-10 2015-09-04 半乳糖改造的免疫球蛋白1抗体

Country Status (5)

Country Link
US (2) US20170253661A1 (cg-RX-API-DMAC7.html)
EP (2) EP3567056A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017528468A (cg-RX-API-DMAC7.html)
CN (2) CN106687481B (cg-RX-API-DMAC7.html)
WO (1) WO2016037947A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017381657B2 (en) * 2016-12-21 2020-07-23 F. Hoffmann-La Roche Ag Method for in vitro glycoengineering of antibodies
CN110100007B (zh) * 2016-12-21 2024-05-28 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的酶的再使用
AU2017384276B9 (en) 2016-12-21 2020-11-26 F. Hoffmann-La Roche Ag In vitro glycoengineering of antibodies
AU2019339895A1 (en) * 2018-09-11 2021-03-11 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
EP4041773A1 (en) * 2019-10-11 2022-08-17 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
US11975066B2 (en) 2020-08-31 2024-05-07 SAB Biotherapeutics, Inc. Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof
EP4119672A1 (en) * 2021-07-14 2023-01-18 Sartorius Stedim Cellca GmbH Method of modulating the extent of galactosylation of proteins in mammalian producer cells
CN114167060B (zh) * 2021-11-25 2022-08-05 辽宁师范大学 一种肝癌生物标志物及检测肝癌的试剂盒
WO2023102398A2 (en) * 2021-11-30 2023-06-08 Sab, Llc Ungulate-derived polyclonal immunoglobulin specific for influenza virus and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1902231A (zh) * 2003-11-05 2007-01-24 格黎卡特生物技术股份公司 具有增加的Fc受体结合亲和性和效应子功能的CD20抗体
WO2013021279A2 (en) * 2011-08-10 2013-02-14 Lfb Biotechnologies Highly galactosylated antibodies
WO2013050335A1 (en) * 2011-10-05 2013-04-11 F. Hoffmann-La Roche Ag Process for antibody g1 glycoform production

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DK1516628T3 (da) 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69907439T3 (de) 1998-05-06 2014-01-02 Genentech, Inc. Reinigung von proteinen durch ionenaustauschchromatographie
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
FR2861080B1 (fr) * 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
CN101506238B (zh) * 2005-06-30 2013-11-06 森托科尔公司 具有提高治疗活性的方法和成分
JP2010514448A (ja) * 2006-12-28 2010-05-06 セントコア・オーソ・バイオテツク・インコーポレーテツド アシアリル化免疫グロブリンを生成するための方法およびベクター
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
MX339809B (es) * 2010-05-27 2016-06-09 Merck Sharp & Dohme Corp * Metodo para preparar anticuerpos con propiedades mejoradas.
BR112013003095B1 (pt) * 2010-08-10 2023-03-28 Glycotope Gmbh Método para controle da meia-vida em circulação de um anticorpo ou um fragmento ou derivado funcional do mesmo, composições de anticorpo, seu usos e seus métodos de produção
AU2014217564B2 (en) * 2013-02-13 2018-11-08 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-HER2 antibodies and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1902231A (zh) * 2003-11-05 2007-01-24 格黎卡特生物技术股份公司 具有增加的Fc受体结合亲和性和效应子功能的CD20抗体
WO2013021279A2 (en) * 2011-08-10 2013-02-14 Lfb Biotechnologies Highly galactosylated antibodies
WO2013050335A1 (en) * 2011-10-05 2013-04-11 F. Hoffmann-La Roche Ag Process for antibody g1 glycoform production

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IgG糖基化修饰及其意义研究进展;衣常红等;《中国免疫学杂志》;20101120;第26卷(第11期);第1053页第3节 *

Also Published As

Publication number Publication date
US20170253661A1 (en) 2017-09-07
EP3191527B1 (en) 2020-01-15
EP3191527A1 (en) 2017-07-19
JP2017528468A (ja) 2017-09-28
CN114181312A (zh) 2022-03-15
US20200325245A1 (en) 2020-10-15
EP3567056A1 (en) 2019-11-13
CN106687481A (zh) 2017-05-17
WO2016037947A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
CN106687481B (zh) 半乳糖改造的免疫球蛋白1抗体
CA2674239C (en) Methods and vectors for generating asialylated immunoglobulins
DK1896071T3 (en) Methods and compositions with increased therapeutic activity
US20120076778A1 (en) Antibodies Against Insulin-Like Growth Factor I Receptor and Uses Thereof
TWI780097B (zh) 於活體外進行抗體之糖基化工程
JP2014508759A (ja) シアリル化抗体の生産の方法
TWI781973B (zh) 用於以活體外進行抗體糖基化工程之方法
KR20190084313A (ko) 항체의 시험관내 글리코조작에 있어서의 효소의 재사용
US20250313646A1 (en) Glycoengineered antibodies
JP2022500371A (ja) 抗体依存性細胞介在性細胞傷害の調節方法
HK1241889A1 (en) Galactoengineered immunoglobulin 1 antibodies
JP2021006540A (ja) ガラクトース操作型免疫グロブリン１抗体
CN101466402A (zh) 糖基化改造的抗体治疗
HK40011889A (en) In vitro glycoengineering of antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1241889

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220322

CF01 Termination of patent right due to non-payment of annual fee
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1241889

Country of ref document: HK